(AOF) – According to a market source, Oddo BHF confirmed its Neutral recommendation and its target price of 14 euros on Adocia. The broker welcomed the start of the phase 3 program in China of BC Lispro (ultra-rapid insulin) in type 1 and 2 diabetes.

The broker points out that the partnership with Tonghua Dongbao offers Adocia the double advantage of partly de-risking the development of its pipeline and having potential access to a major diabetes market, namely China, where its BioChaperone technology would allow it to have a suitable positioning (BioChaperone improves insulins whose patents have expired, which would potentially allow it to offer a treatment at a lower cost).